Townsend John 4

What Happened John Townsend, Chief Financial Officer of Unicycive Therapeutics, was granted an award of 169,500 restricted stock units (RSUs) on 2026-05-14. The award is reported as a derivative acquisition at $0.00 per share (no cash paid). These RSUs are payable solely in common stock of the company.

Key Details

• Transaction date: 2026-05-14; Form 4 filed 2026-05-20 (filing date shown on accession).
• Transaction type/code: Award/Grant (A); 169,500 RSUs @ $0.00 (derivative).
• Vesting: The RSUs vest 1/3 on each anniversary of the grant date for three years, subject to continued service (see footnote F1).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Notable footnote: F1 confirms the award is payable solely in common stock and vests over three years.
• No indication in this filing that the grant was part of a 10b5-1 plan, a sale, option exercise, tax withholding, or a cash transaction.

Context This was a time‑based equity grant (RSUs), common for executive compensation, rather than an open‑market purchase or sale. RSU grants compensate and retain executives and do not immediately represent a market purchase signal until vested shares are sold.